Metabolic-Associated Steatotic Liver Disease (MASLD)
Formerly called nonalcoholic fatty liver disease (NAFLD), MASLD encompasses a spectrum from simple steatosis to steatohepatitis (MASH/NASH) and cirrhosis. It is strongly linked to insulin resistance, obesity, dyslipidemia, and hypertension.
Risk Factors
- Central obesity, metabolic syndrome, type 2 diabetes
- Dyslipidemia, polycystic ovary syndrome, obstructive sleep apnea
- Genetic variants (PNPLA3, TM6SF2, MBOAT7)
- Sedentary lifestyle, high-fructose or ultra-processed diets
- Medications (amiodarone, tamoxifen, steroids) occasionally contribute
Symptoms
- Often asymptomatic; may have fatigue, RUQ discomfort
- Hepatomegaly on exam
- Advanced disease: signs of cirrhosis (ascites, jaundice, varices)
Diagnosis & Staging
- Elevated ALT/AST (often ALT > AST) but may be normal
- Ultrasound showing steatosis; MRI-PDFF for quantifying fat
- ELFTs/FibroScan to assess fibrosis (liver stiffness measurement)
- Noninvasive scores: FIB-4, NAFLD fibrosis score
- Liver biopsy if fibrosis stage uncertain or to confirm NASH for clinical trials
- Exclude other causes (viral hepatitis, alcohol, autoimmune, Wilson's)
Treatment & Management
Lifestyle Interventions
- Weight loss 7–10% via calorie deficit + exercise can improve NASH/fibrosis
- Mediterranean diet, reduced fructose and saturated fat intake
- Aerobic + resistance training 150+ minutes/week
- Limit alcohol (even moderate intake can worsen disease)
Medications (off-label/indicated for comorbidities)
- Pioglitazone for biopsy-proven NASH (especially with T2D)
- GLP-1 receptor agonists (semaglutide, tirzepatide) for weight loss + liver improvement
- Vitamin E 800 IU/day in non-diabetic NASH (monitor for risks)
- Statins for dyslipidemia (safe in MASLD)
Emerging Approved Therapies
- FXR agonists, THR-β agonists, FGF21 analogs under regulatory review
Comorbidity Management
- Tight glycemic control, treat hypertension and dyslipidemia
- Vaccinate (HAV, HBV), screen for sleep apnea
- Evaluate for bariatric surgery in qualifying patients
Advanced Disease
- HCC surveillance (ultrasound ± AFP every 6 months) when cirrhosis present
- Manage portal hypertension, variceal screening, transplant referral if decompensated
Living with MASLD
- Track weight, waist circumference, labs, imaging, medications
- Build sustainable nutrition habits; consider dietitian support
- Address mental health; body image and chronic fatigue can be challenging
- Celebrate incremental progress (1–2% weight loss still improves insulin sensitivity)
Complications
- Progressive fibrosis, cirrhosis, hepatocellular carcinoma
- Cardiovascular disease (leading cause of death in MASLD)
- Type 2 diabetes, CKD
Research & Future Directions
Precision medicine, combination regimens, gut microbiome modulation, and digital coaching are transforming care.
Experimental & Emerging Treatments
- FXR Agonists (obeticholic acid, tropifexor): Target bile acid pathways to reduce fibrosis.
- Thyroid Hormone Receptor-β Agonists (resmetirom): Improve lipids and liver fat with minimal cardiac effects.
- FGF21/FGF19 Analogues: Regulate metabolism, reduce inflammation and fibrosis.
- Microbiome-Based Therapies: Probiotics, fecal transplant, and postbiotics explore gut-liver axis modulation.
Track MASLD with Diagnoza.care
Make Metabolic Wins Visible – Log weight, waist, labs (ALT/AST, lipids, A1C), imaging, medications, diet/exercise routines, sleep, and stress; schedule hepatology/endocrinology visits; capture side effects; and let the AI companion surface trends tied to liver improvement or deterioration.
Medical Disclaimer: Informational only. Work with your hepatologist/endocrinologist to confirm diagnosis, monitor fibrosis, and tailor lifestyle/pharmacologic therapies.
Sources: American Association for the Study of Liver Diseases, European Association for the Study of the Liver, Global Liver Institute